Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi : A participant‐level pooled analysis of three phase 3 LixiLan randomized controlled trials
Authors' conclusion
iGlarLixi achieved improvements in dTIR, with low dTBR values, providing further evidence to inform clinical outcomes with the use of iGlarLixi.
Study context
- Population
- People with T2D in LixiLan-L, LixiLan-O and LixiLan-Gpooled LixiLan trials
- Participants
- 2,420 people
- Comparison
- iGlarLixi vs iGlar, Lixi or GLP-1 RA
- iGlarLixin = 1,093
- iGlarn = 836reference
- Lixin = 234reference
- GLP-1 RAn = 257reference
- Outcome
- Derived TIR (70-180 mg/dL) from seven-point SMBG profiles
- Follow-up
- Baseline to end of treatment
Methodological detailsparticipant-level pooled analysis, LixiLan-L, LixiLan-O and LixiLan-G trials
- Participant-level pooled analysis
- LixiLan-L, LixiLan-O and LixiLan-G trials
Pooled result
As reported in the abstract
Change in LS mean dTIR · baseline to EOT
iGlarLixi
25.7%
Least square (LS) mean
iGlar
15.8%
LS mean
Lixi
11.7%
LS mean
GLP-1 RA
16.2%
LS mean
Further pooled results
Derived time-in-range (dTIR) change by age subgroup (<65 years, n = 1690; ≥65 years, n = 713) · baseline to end of treatment (EOT)
- Numerically greater improvements in LS mean dTIR with iGlarLixi vs iGlar, Lixi or GLP-1 RA in both age subgroups
Safety
Mean
| Outcome | iGlarLixi | iGlar | Lixi | GLP-1 RA |
|---|---|---|---|---|
| Derived TBR (<70 mg/dL) · EOT | 0.71% (SD 3.4%) | 0.61% (SD 3.2%) | 0.08% (SD 1.0%) | 0.0% (SD 0.0%) |
Original publication
Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi : A participant‐level pooled analysis of three phase 3 LixiLan randomized controlled trials. Diabetes Obes Metab. Published 8 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →